|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Banyan Biomarkers Works with Emory University to Analyze Biomarkers in the Clinical Trial of Progesterone in Traumatic Brain Injury
8/4/2011 7:59:14 AM
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc. will partner with Emory University through a grant from the National Institutes of Health to measure biomarkers in the blood of traumatic brain injury (TBI) patients. The five-year grant of $2.2 million was awarded to Michael Frankel, MD, Professor of Neurology at Emory School of Medicine, with partners Banyan Biomarkers, Inc., the Medical University of South Carolina, the University of Pittsburgh and the University of Michigan. The research team will study biomarkers in the blood of TBI patients enrolled in the phase III clinical trial, ProTECT III (Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment), which is assessing the efficacy of progesterone in the treatment of TBI.
|
|
|
|
|
|
|
|
|
|
|